Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma. Tang WZ, Xu WZ, Liu TH. Oral Oncol 2024;159:107065.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tang WZ, Xu WZ, Liu TH. Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma. Oral Oncol 2024;159:107065.
PMID: 39366057